Linagliptin - Boehringer Ingelheim/Eli Lilly

Drug Profile

Linagliptin - Boehringer Ingelheim/Eli Lilly

Alternative Names: BI 1356; BI 1356 BS; Dipeptidyl peptidase IV inhibitor - Boehringer Ingelheim; Ondero; Tradjenta; Trajenta; Trayenta; Trazenta

Latest Information Update: 15 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly
  • Class Alkynes; Antihyperglycaemics; Piperidines; Purines; Quinazolines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Diabetic nephropathies

Most Recent Events

  • 04 Oct 2018 Efficacy and Adverse events data from the phase IV CARMELINA trial in Type-2 diabetes mellitus released by Boehringer Ingelheim and Eli Lilly
  • 30 Sep 2018 Eli Lilly files sNDA for inclusion of data from CARMELINA trial to the label of linagliptin treatment of patients with Type-2 diabetes mellitus in USA
  • 21 Aug 2018 Boehringer Ingelheim completes the phase III CAROLINA trial in Type-2 diabetes mellitus in Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Czech Republic, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Norway, Peru, Philippines, Portugal, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Tunisia, Ukraine, United Kingdom and USA (NCT01243424)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top